Lambert-Eaton Myasthenic Syndrome (LEMS)

1. Clinical Overview

Summary

Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune disorder of the neuromuscular junction (NMJ) characterized by defective neurotransmitter release from presynaptic nerve terminals. Unlike Myasthenia Gravis, which targets postsynaptic acetylcholine receptors, LEMS results from autoantibodies directed against presynaptic voltage-gated calcium channels (VGCC), specifically the P/Q-type channels critical for calcium-mediated acetylcholine vesicle fusion and release. [1,2]

The clinical hallmark is proximal muscle weakness, predominantly affecting the lower limbs, producing the characteristic complaint of "heavy legs" and difficulty rising from a chair or climbing stairs. The pathognomonic feature distinguishing LEMS from other neuromuscular disorders is post-tetanic potentiation or "facilitation"

• a paradoxical improvement in strength and reflexes following brief maximal voluntary contraction or repetitive nerve stimulation. This contrasts sharply with the fatigability seen in Myasthenia Gravis. [3]

A critical aspect of LEMS diagnosis is its strong association with underlying malignancy. Approximately 50-60% of LEMS cases are paraneoplastic, most commonly associated with Small Cell Lung Cancer (SCLC). [4] In these cases, the tumor expresses VGCC antigens on its surface, triggering an immune response that cross-reacts with neuronal VGCCs. Remarkably, LEMS symptoms typically precede cancer diagnosis by months to years, making LEMS recognition an important oncological warning signal. The remaining 40-50% of cases are non-paraneoplastic (autoimmune) and occur without malignancy. [5]

Autonomic dysfunction is another defining feature, present in over 80% of patients. Manifestations include xerostomia (dry mouth), constipation, erectile dysfunction, impaired pupillary responses, and orthostatic hypotension. These autonomic features, combined with the characteristic weakness pattern and electrophysiological findings, form the diagnostic triad of LEMS. [6]

Management involves a multi-pronged approach: aggressive screening for underlying malignancy (particularly SCLC), symptomatic treatment with 3,4-diaminopyridine (amifampridine) to enhance neuromuscular transmission, and immunosuppressive therapy in refractory cases. When associated with SCLC, successful treatment of the underlying cancer frequently leads to improvement or resolution of neurological symptoms. [7,8]

Key Facts

• Mechanism: IgG autoantibodies (primarily IgG1 and IgG3 subclasses) target P/Q-type voltage-gated calcium channels at presynaptic nerve terminals, reducing calcium influx and subsequently decreasing acetylcholine quantal release. [9]

• The "Warm-Up" Phenomenon: Rapid repetitive muscle contraction allows residual calcium to accumulate in presynaptic terminals, temporarily overcoming the calcium entry defect and producing a transient surge in acetylcholine release. This results in augmentation of muscle strength and return of previously absent reflexes - the opposite pattern to the exercise-induced fatigue seen in Myasthenia Gravis. [3]

• Paraneoplastic Association: In 90% of SCLC-associated LEMS cases, the neurological syndrome manifests before cancer detection, with a median lead time of 6-12 months. LEMS serves as an early sentinel marker for occult malignancy. [4,10]

• Autonomic Dysfunction: Xerostomia (dry mouth) occurs in > 80% of patients and is often the first symptom. Other features include constipation (40-50%), erectile dysfunction in males (40%), impaired lacrimation, and orthostatic hypotension. These result from antibody-mediated dysfunction of autonomic ganglia. [6,11]

• SOX1 Antibodies: Anti-SOX1 antibodies are highly specific (95%) for SCLC-associated LEMS and are rarely found in non-paraneoplastic cases. Their presence mandates intensive cancer screening. [12]

• Electrophysiological Signature: Low-amplitude compound muscle action potentials (CMAP) at rest with > 100% increment following high-frequency (20-50 Hz) repetitive nerve stimulation or brief maximal voluntary contraction is diagnostic. [13]

• Epidemiology: LEMS is rare, with an estimated prevalence of 3.4 per million population - approximately 100 times rarer than Myasthenia Gravis. Median age at diagnosis is 60 years, with male predominance (2:1) in paraneoplastic cases reflecting SCLC demographics. [14]

Clinical Pearls

"The Handshake Sign": When asking a patient to squeeze your hand firmly, the initial grip is weak. Requesting rapid repetitive squeezing (10-20 times) results in progressive strengthening of grip force - a bedside demonstration of post-tetanic facilitation.

"Reflexes Return": Testing the knee jerk reflex initially shows hyporeflexia or areflexia. After the patient performs maximal isometric quadriceps contraction for 10 seconds, immediate repeat testing reveals augmented or restored reflexes - this is post-exercise facilitation of reflexes.

"Metallic Taste": Dysgeusia (altered taste, often metallic) is a recognized autonomic symptom in LEMS, distinct from medication side effects.

"Cancer Precedes Age": In patients under 50 with LEMS, the likelihood of non-paraneoplastic etiology increases significantly. Conversely, in patients over 50 (especially smokers), paraneoplastic LEMS with SCLC should be the working diagnosis until proven otherwise.

"Better Paradox": LEMS patients with SCLC have better overall survival compared to SCLC patients without LEMS, attributed to enhanced anti-tumor immune surveillance. [15]

---

2. Epidemiology

Incidence and Prevalence

Lambert-Eaton Myasthenic Syndrome is a rare autoimmune neuromuscular disorder with distinct epidemiological characteristics:

Demographics

Age Distribution:

• Paraneoplastic LEMS: Median age 60-65 years (range 40-75)
• Non-paraneoplastic LEMS: Median age 50-55 years (broader range 20-80)
• Bimodal distribution reflects different etiological subgroups [14]

Sex Distribution:

• Paraneoplastic LEMS: Male predominance 2-3:1 (mirrors SCLC demographics and smoking prevalence)
• Non-paraneoplastic LEMS: Slight male predominance 1.5:1 [18]

Ethnicity:

• Data limited, but appears to affect all ethnic groups
• Prevalence studies predominantly from European and North American populations
• Geographic variation may reflect SCLC incidence patterns [14]

Risk Factors

For Paraneoplastic LEMS:

• Active smoking (> 90% of SCLC-LEMS cases have significant smoking history)
• Age > 40 years
• Male sex
• Pre-existing autoimmune conditions (controversial association) [4,19]

For Non-Paraneoplastic LEMS:

• HLA-B8, HLA-DR3, HLA-DQ2 haplotypes confer increased susceptibility
• Family history of autoimmune disease
• Coexistent autoimmune disorders (thyroid disease, vitiligo, celiac disease) [20]

Temporal Trends

• Recognition and diagnosis have improved since the 1980s with availability of VGCC antibody testing
• Earlier detection of SCLC through CT screening may alter presentation patterns
• Increasing use of 3,4-diaminopyridine has improved symptomatic management outcomes [8]

---

3. Aetiology & Pathophysiology

Molecular Pathogenesis

The Presynaptic Calcium Channel Complex

Normal neuromuscular transmission requires a precisely coordinated sequence:

1. Action potential arrival at the presynaptic motor nerve terminal
2. Membrane depolarization opens voltage-gated calcium channels (VGCCs)
3. Calcium influx through P/Q-type VGCCs (Cav2.1 channels)
4. Vesicle fusion triggered by calcium binding to synaptotagmin
5. Acetylcholine release into the synaptic cleft
6. Postsynaptic depolarization via nicotinic acetylcholine receptor activation [21]

In LEMS, autoantibodies disrupt step 3, the critical calcium entry phase.

Autoantibody Targets

Primary Target - P/Q-type VGCC (Cav2.1):

• Present in 85-95% of LEMS patients (both paraneoplastic and non-paraneoplastic)
• IgG antibodies bind to extracellular epitopes on the α1A subunit
• Antibody binding causes:
  • Direct channel blockade (reduced opening probability)
  • Cross-linking and internalization (downregulation of channel density)
  • Complement-mediated channel destruction [9,22]

Secondary Targets:

• N-type VGCCs (Cav2.2): Present in 30-40% of cases, often co-occurring with P/Q antibodies
• Synaptotagmin: A calcium sensor protein; antibodies found in some cases
• Other presynaptic proteins: VAMP, neurexin [23]

The Antibody-Mediated Attack

Mechanism of Channel Loss:

1. Antibody binding to VGCC α1A subunit external loops
2. Cross-linking of adjacent channels by bivalent IgG
3. Antigenic modulation - internalization and degradation via endocytosis
4. Complement activation (C3, C5b-9 membrane attack complex) causing channel lysis
5. Net result: 50-70% reduction in VGCC density at active zones [24]

Functional Consequences:

• Reduced calcium influx per action potential
• Decreased probability of vesicle fusion
• Quantal content (number of acetylcholine vesicles released per impulse) drops from ~100 to ~20-40
• Endplate potentials fail to reach threshold for muscle fiber action potential generation
• Clinical result: Muscle weakness [25]

The Facilitation Phenomenon

Why does strength improve with exercise?

Despite reduced VGCC numbers, the remaining functional channels exhibit normal kinetics. During high-frequency stimulation:

1. Residual calcium accumulation: Incomplete calcium clearance between stimuli allows intracellular calcium to build up
2. Calcium sensor saturation: Even with reduced influx per stimulus, cumulative calcium eventually saturates synaptotagmin
3. Enhanced vesicle fusion probability: The calcium threshold for fusion is achieved
4. Massive quantal release: A surge of acetylcholine release occurs
5. Brief strength improvement: Lasts seconds to minutes until calcium dissipates [26]

This explains:

• Post-exercise potentiation of reflexes
• Improved grip strength with repetitive contractions

• 100% CMAP increment on high-frequency RNS

Paraneoplastic vs. Non-Paraneoplastic LEMS

Paraneoplastic LEMS (SCLC-Associated)

The Onconeural Antigen Hypothesis:

1. SCLC tumor cells (neuroendocrine origin) express VGCCs on their surface for calcium-dependent hormone secretion
2. Immune response to tumor antigens includes VGCC-directed antibodies
3. Cross-reactivity: Anti-tumor antibodies recognize identical VGCC epitopes at neuromuscular junctions
4. Neurological syndrome develops as collateral damage from anti-tumor immunity [27]

Supporting Evidence:

• SCLC tissue samples express high densities of P/Q-type VGCCs [28]
• LEMS patients with SCLC show enhanced tumor-specific T-cell responses [29]
• Successful SCLC treatment often improves LEMS symptoms [7]

SOX1 Antibodies:

• SOX1 (SRY-box transcription factor 1) expressed in SCLC and CNS neurons
• Anti-SOX1 antibodies present in 50-65% of SCLC-LEMS but less than 5% of non-paraneoplastic LEMS
• Serves as a biomarker distinguishing paraneoplastic from autoimmune etiology [12]

Non-Paraneoplastic (Autoimmune) LEMS

Idiopathic Autoimmunity:

• Genetic susceptibility: HLA-B8-DR3-DQ2 haplotype increases risk 6-8 fold [20]
• Loss of tolerance: Unclear trigger for VGCC autoimmunity
• Association with other autoimmune diseases: Thyroid disease (15%), vitiligo, celiac disease [30]
• Chronic course: More stable, less aggressive than paraneoplastic form
• Better response to immunosuppression: Prednisolone and azathioprine often effective [31]

Autonomic Dysfunction Mechanism

VGCC antibodies also target autonomic ganglia:

• Parasympathetic ganglia: Reduced acetylcholine release causes xerostomia, constipation, erectile dysfunction
• Sympathetic ganglia: Impaired norepinephrine release contributes to orthostatic hypotension
• Pupillary abnormalities: Reduced light reflex, anisocoria [11]

---

4. Clinical Presentation

Cardinal Motor Symptoms

Proximal Weakness

Distribution Pattern:

• Lower limbs >> Upper limbs (80-90% present with leg symptoms)
• Proximal >> Distal (hip flexors, quadriceps most affected)
• Symmetrical in most cases [3]

Patient Descriptions:

• "Heavy legs"
• most common complaint
• Difficulty rising from chair without arm support
• Trouble climbing stairs or getting out of a car
• Waddling gait
• Frequent falls

Natural History:

• Insidious onset over weeks to months
• Progressive course if untreated
• Rarely presents acutely (differentiates from Guillain-Barré)

The "Warm-Up" Effect

Characteristic Pattern:

• Weakness most pronounced in morning or after rest
• Transient improvement with initial activity (first 10-30 seconds)
• Subsequent decline in strength with sustained exercise
• Differs from MG where initial strength is relatively normal but rapidly fatigues [3]

Clinical Testing:

• Grip strength: Weak initially → Strengthens with rapid repetition → Fatigues again
• Shoulder abduction: Begins weak → Improves after 5-10 repetitions
• Knee extension: Weak → Briefly improves with isometric contraction

Ocular and Bulbar Involvement

Less Common than MG:

• Ptosis: 20-40% (usually mild, not the presenting feature)
• Diplopia: 15-30% (less prominent than in MG)
• Dysarthria: 10-20%
• Dysphagia: 10-20%
• Absence of prominent bulbar symptoms helps distinguish from MG [32]

Respiratory Involvement

• Rare at presentation (less than 5%)
• Can occur in severe untreated disease
• Respiratory crisis much less common than in MG
• Forced vital capacity monitoring recommended in advanced cases [33]

Autonomic Symptoms

Cholinergic Dysfunction

Xerostomia (Dry Mouth):

• Present in 80-95% of patients
• Often the first symptom, preceding weakness by months
• Difficulty swallowing dry foods
• Increased dental caries
• Nocturnal water consumption [6]

Other Parasympathetic Features:

• Dry eyes (keratoconjunctivitis sicca): 40-50%
• Constipation: 40-50%
• Bladder dysfunction (urinary retention): 20%
• Erectile dysfunction (males): 40-60%
• Decreased sweating: 15-20% [11]

Adrenergic Dysfunction

Orthostatic Hypotension:

• Present in 30-40%
• Drop in systolic BP > 20 mmHg on standing
• Dizziness, presyncope
• Falls risk [34]

Pupillary Abnormalities:

• Sluggish light reflex
• Anisocoria (unequal pupils)
• Tonic pupils (slow redilation after constriction) [11]

Physical Examination Findings

Motor Examination

Autonomic Examination

• Dry oral mucosa (reduced saliva pool under tongue)
• Reduced tear film on Schirmer test
• Orthostatic vital signs: Drop in BP without compensatory HR rise
• Pupillary light reflex: Sluggish or absent

Respiratory Examination

• Reduced chest expansion in severe cases
• Paradoxical abdominal breathing (diaphragmatic weakness)
• Weak cough (rarely)

---

5. Differential Diagnosis

Primary Differentials

1. Myasthenia Gravis (MG)

Most Important Differential:

Key Distinguishing Test: High-frequency RNS or post-exercise CMAP increment [35]

2. Polymyositis/Dermatomyositis

Inflammatory Myopathies:

Similarities to LEMS:

• Proximal muscle weakness
• Subacute progression
• Elevated ESR/CRP (sometimes)

Differences:

• Muscle tenderness (absent in LEMS)
• Elevated CK (normal in LEMS)
• Normal reflexes (reduced in LEMS)
• EMG: Myopathic changes vs. neuromuscular junction defect
• Muscle biopsy: Inflammatory infiltrates vs. normal in LEMS [36]

3. Guillain-Barré Syndrome (GBS)

Acute Inflammatory Demyelinating Polyneuropathy:

Differences from LEMS:

• Acute onset (hours to days) vs. subacute (weeks to months)
• Distal > proximal weakness vs. proximal predominance
• Ascending pattern (legs → arms → respiratory) vs. static proximal distribution
• Sensory symptoms prominent vs. absent in LEMS
• CSF: Elevated protein in GBS vs. normal in LEMS
• NCS: Demyelinating pattern vs. NMJ defect [37]

4. Mitochondrial Myopathy

Chronic Progressive External Ophthalmoplegia (CPEO):

• Ptosis and ophthalmoplegia (without diplopia - symmetrical)
• Exercise intolerance
• Differences: No autonomic features, no post-exercise facilitation, elevated lactate, ragged red fibers on biopsy [38]

5. Motor Neuron Disease (MND/ALS)

Progressive Muscular Atrophy:

• Progressive weakness
• Differences: Fasciculations, muscle atrophy, upper motor neuron signs, no autonomic features, no facilitation, EMG shows denervation [39]

When to Suspect LEMS

Red Flag Combinations:

• Proximal weakness + hyporeflexia + dry mouth
• Weakness that improves briefly with exercise
• Smoker > 50 years with unexplained weakness
• Known SCLC with new-onset weakness
• Muscle weakness + normal CK + normal EMG (myopathic pattern)

---

6. Investigations

Electrophysiology - The Diagnostic Cornerstone

Repetitive Nerve Stimulation (RNS)

Standard Protocol:

1. Baseline CMAP Recording:

   • Compound muscle action potential amplitude measured at rest
   • Low amplitude (less than 5 mV in ~50% of LEMS patients; normal is 5-10 mV) [13]

2. Low-Frequency RNS (2-3 Hz):

   • Trains of 5-10 stimuli at low frequency
   • Decremental response (> 10% drop from first to fourth CMAP)
   • Similar to MG pattern
   • Sensitivity: 60-70% [13]

3. High-Frequency RNS (20-50 Hz) or Post-Exercise Facilitation:

   • Patient performs maximal voluntary contraction for 10 seconds, OR
   • High-frequency stimulation (50 Hz for 10 seconds)
   • Immediate repeat CMAP measurement
   • Incremental response: > 100% increase in CMAP amplitude
   • Diagnostic of LEMS (specificity > 95%) [40]

Technical Considerations:

• Test multiple nerves (median, ulnar, peroneal) to maximize sensitivity
• Post-exercise facilitation lasts only 1-2 minutes; timing is critical
• Maximal voluntary contraction must be truly maximal (10/10 effort)

Single-Fiber EMG (SFEMG)

Most Sensitive Test (but Non-Specific):

• Measures neuromuscular transmission stability
• Increased jitter (variability in inter-potential interval): Sensitivity ~95%
• Blocking (intermittent failure of transmission): Present in severe cases
• Not specific to LEMS (also abnormal in MG, neuropathy, myopathy)
• Useful when RNS is negative but clinical suspicion high [41]

Needle EMG

Typically Normal:

• No denervation (excludes motor neuron disease, neuropathy)
• No myopathic changes (excludes polymyositis)
• May see small motor unit potentials due to reduced fiber recruitment
• Diagnostic value: Exclusion of alternative neuromuscular disorders [42]

Serological Testing

Anti-VGCC Antibodies

P/Q-Type VGCC Antibodies (α1A Subunit):

N-Type VGCC Antibodies:

• Present in 30-40% of LEMS (often co-occurring with P/Q antibodies)
• Less specific than P/Q antibodies [23]

Antibody Titer and Clinical Correlation:

• Titers do not reliably predict clinical severity
• Antibody reduction with immunotherapy may precede clinical improvement
• Serial titers not routinely used for monitoring [44]

Anti-SOX1 Antibodies

Paraneoplastic Biomarker:

Clinical Application:

• Positive SOX1 → Intensive cancer screening mandatory
• Negative SOX1 in patient > 50 with smoking history → Still screen for SCLC
• Most useful in younger patients to stratify cancer risk

Other Autoantibodies

Associated Antibodies (Less Specific):

• Anti-synaptotagmin
• Anti-neurexin
• Thyroid antibodies (in non-paraneoplastic LEMS)
• ANA, RF (excluding other autoimmune conditions) [23,30]

Oncological Screening

Mandatory in All LEMS Patients:

Initial Screening (All Patients)

1. CT Chest, Abdomen, Pelvis with IV Contrast:

   • Primary modality for SCLC detection
   • Sensitivity ~80-85% for thoracic malignancy
   • Look for hilar/mediastinal lymphadenopathy, lung masses [45]

2. Whole-Body FDG-PET/CT:

   • If CT chest is negative but high clinical suspicion (age > 50, smoker, SOX1+)
   • Increased sensitivity for occult SCLC and other malignancies
   • Detects metabolically active tumors not visible on anatomical imaging [46]

3. Tumor Markers:

   • Neuron-specific enolase (NSE): Elevated in 60% of SCLC
   • ProGRP (pro-gastrin-releasing peptide): More specific for SCLC
   • Not diagnostic alone but support screening strategy [47]

Follow-Up Surveillance (If Initial Screening Negative)

The DELTA-P Score predicts cancer risk:

• Score ≥3: High risk - CT every 3 months for 2 years, then every 6 months for 3 years
• Score less than 3: Lower risk - CT every 6 months for 2 years, then annually for 3 years [48]

Rationale for Prolonged Surveillance:

• 90% of SCLC cases diagnosed within first 2 years of LEMS onset
• Small tumors may be initially undetectable
• Early SCLC detection improves survival [4,10]

Other Investigations

Pulmonary Function Tests

• Indicated if: Respiratory symptoms, severe weakness, or pre-treatment assessment
• Key measurements:
  • Forced Vital Capacity (FVC)
  • Maximal Inspiratory Pressure (MIP)
  • Maximal Expiratory Pressure (MEP)
• Threshold for concern: FVC less than 60% predicted or MIP less than 30 cm H₂O [33]

Autonomic Function Testing

• Quantitative sudomotor axon reflex test (QSART)
• Heart rate variability (R-R interval variation)
• Tilt-table testing for orthostatic hypotension
• Clinical utility: Limited; diagnosis typically clinical [34]

Baseline Laboratory Tests

• Complete Blood Count: Rule out anemia, infection
• Creatine Kinase: Normal in LEMS (elevated in myositis)
• Thyroid Function: Exclude thyroid myopathy, screen for autoimmune overlap
• Renal and Liver Function: Pre-treatment baseline for immunosuppression
• ESR/CRP: Usually normal (elevated in inflammatory myopathy)

---

7. Classification and Staging

Etiological Classification

1. Paraneoplastic LEMS (50-60%)

Small Cell Lung Cancer (90-95% of paraneoplastic cases):

• Limited stage (confined to hemithorax): Better prognosis
• Extensive stage (metastatic): Poorer prognosis
• LEMS onset typically precedes SCLC diagnosis by 6-12 months [4]

Other Malignancies (5-10% of paraneoplastic cases):

• Lymphoproliferative disorders (lymphoma, chronic lymphocytic leukemia)
• Prostate cancer
• Thymoma (rare overlap with MG features)
• Breast cancer [49]

2. Non-Paraneoplastic (Autoimmune) LEMS (40-50%)

Idiopathic Autoimmune:

• No identifiable malignancy after 2-5 years surveillance
• Younger age of onset (mean 40-50 years)
• HLA-B8-DR3-DQ2 association
• Often co-exists with other autoimmune diseases [5,20]

Clinical Severity Grading

No Standardized Staging System, but functional assessment scales used:

Quantitative Myasthenia Gravis Score (Modified for LEMS)

Autonomic Severity

• Mild: Dry mouth only
• Moderate: Multiple autonomic symptoms (dry mouth, constipation, erectile dysfunction)
• Severe: Orthostatic hypotension with syncope, bladder dysfunction requiring catheterization

---

8. Management

Management Algorithm

         LEMS DIAGNOSIS CONFIRMED
                  ↓
    ┌─────────────────────────────┐
    │  SIMULTANEOUS APPROACH:    │
    │  1. Cancer Screening        │
    │  2. Symptomatic Treatment   │
    │  3. Immunotherapy (if needed)│
    └─────────────────────────────┘
                  ↓
        ┌────────┴────────┐
     CANCER FOUND?    CANCER NOT FOUND
        │                  │
        ↓                  ↓
    SCLC TREATMENT    NON-PARANEOPLASTIC
    (Chemo/Radio)       MANAGEMENT
        │                  │
        ↓                  ↓
    3,4-DAP +         3,4-DAP ±
    Immunotherapy     Immunosuppression
        │                  │
        └────────┬─────────┘
                 ↓
        ONGOING MONITORING
        - Clinical strength
        - Autonomic symptoms
        - Cancer surveillance
        - Treatment side effects

Symptomatic Treatment - First-Line

3,4-Diaminopyridine (Amifampridine)

Mechanism of Action:

• Blocks voltage-gated potassium channels (Kv1.1, Kv1.2) at presynaptic nerve terminals
• Prolonged action potential duration → VGCCs remain open longer
• Increased calcium influx through residual functional VGCCs
• Enhanced acetylcholine vesicle release → Improved neuromuscular transmission [50]

Formulations:

Dosing:

• Starting dose: 15 mg/day in 3 divided doses (5 mg TDS)
• Titration: Increase by 5 mg increments every 3-4 days
• Typical effective dose: 30-60 mg/day (range 15-80 mg/day)
• Maximum dose: 80 mg/day (doses > 100 mg/day increase seizure risk)
• Administration: With food to reduce GI side effects [8,51]

Efficacy:

• Muscle strength improvement: 30-40% increase in limb strength scores
• Response rate: 80-90% of patients report subjective benefit
• Onset: Within hours to days
• Autonomic improvement: Variable; some improvement in dry mouth (40% of patients) [52]

Adverse Effects:

Contraindications:

• History of seizures or epilepsy
• Uncontrolled asthma (can precipitate bronchospasm)
• QTc > 450 ms
• Severe renal impairment (eGFR less than 30 mL/min; dose reduction required)

Monitoring:

• Baseline ECG (QTc measurement)
• Repeat ECG at 1 month and then annually
• Clinical strength assessment (e.g., timed up-and-go test)
• Autonomic symptom diary [8]

Pyridostigmine (Acetylcholinesterase Inhibitor)

Limited Efficacy in LEMS:

• Mechanism: Inhibits acetylcholine breakdown in synaptic cleft
• Problem: LEMS is a presynaptic disorder (reduced ACh release), not postsynaptic (as in MG)
• Response rate: Only 10-20% of LEMS patients benefit (contrast with > 90% in MG)
• Dosing: 60 mg TDS-QID if trialed
• Use: Occasionally added to 3,4-DAP for incremental benefit [53]

Immunotherapy - Second-Line

Indications:

• Inadequate response to 3,4-DAP alone
• Non-paraneoplastic LEMS requiring disease modification
• Paraneoplastic LEMS with persistent symptoms despite cancer treatment

Corticosteroids

Prednisolone:

• Dosing:
  • "Starting: 0.5-1 mg/kg/day (typically 40-60 mg/day)"
  • Taper once response achieved (over 3-6 months)
  • "Maintenance: 5-10 mg/day"
• Efficacy: 60-70% response rate in non-paraneoplastic LEMS
• Onset: 2-6 weeks
• Side effects: Standard steroid toxicity (weight gain, hyperglycemia, osteoporosis, infection risk) [54]

Steroid-Sparing Immunosuppressants

Azathioprine:

• Dosing: 2-3 mg/kg/day (typical 100-150 mg/day)
• Mechanism: Purine synthesis inhibitor
• Efficacy: 50-60% response rate; allows steroid dose reduction
• Onset: Slow (3-6 months to full effect)
• Monitoring: TPMT level pre-treatment; FBC and LFTs monthly for 3 months, then 3-monthly
• Toxicity: Bone marrow suppression, hepatotoxicity, GI upset [55]

Mycophenolate Mofetil:

• Dosing: 1-2 g/day in divided doses
• Alternative to azathioprine if intolerant or TPMT deficiency
• Monitoring: FBC, renal function [56]

Intravenous Immunoglobulin (IVIg)

Indications:

• Acute severe weakness
• Bridge therapy before immunosuppression takes effect
• Patients unable to tolerate oral medications
• Refractory LEMS

Dosing:

• Standard: 2 g/kg divided over 2-5 days (e.g., 0.4 g/kg/day × 5 days)
• Maintenance (if needed): 1 g/kg every 3-4 weeks

Efficacy:

• Response rate: 60-80%
• Onset: Within days to 1 week
• Duration: 4-8 weeks (temporary benefit)

Adverse Effects:

• Headache (common; reduce infusion rate)
• Thromboembolism (especially in elderly, immobile)
• Hypersensitivity reactions
• Aseptic meningitis (rare)
• Renal dysfunction (avoid sucrose-containing formulations) [57]

Plasma Exchange (PLEX)

Indications:

• Severe acute LEMS crisis
• Rapid deterioration
• Pre-surgical optimization

Protocol:

• 5-7 exchanges over 10-14 days
• Exchange 1-1.5 plasma volumes per session

Efficacy:

• Response rate: 70-90%
• Onset: Within days
• Duration: 2-4 weeks (temporary)

Limitations:

• Requires central venous access
• Resource-intensive
• Temporary benefit (requires concurrent immunosuppression) [58]

Oncological Treatment

Cornerstone of Paraneoplastic LEMS Management:

SCLC Treatment

Chemotherapy:

• Platinum-based regimens: Cisplatin or carboplatin + etoposide
• Standard: 4-6 cycles
• Neurological improvement: 50-70% of LEMS patients show symptom improvement with successful SCLC response [7]

Radiotherapy:

• Limited-stage SCLC: Concurrent chemoradiotherapy + prophylactic cranial irradiation
• Extensive-stage: Palliative radiotherapy for symptomatic metastases

Immunotherapy (Checkpoint Inhibitors):

• Emerging role: Atezolizumab, durvalumab in extensive-stage SCLC
• Caution: Can exacerbate autoimmune phenomena including LEMS
• Monitoring: Close neurological surveillance if used [59]

Non-SCLC Malignancies

• Treatment per standard oncological protocols
• Neurological improvement variable depending on tumor type

Treatment of Specific Complications

Respiratory Failure

Rare but Life-Threatening:

• Supportive care: Oxygen, non-invasive ventilation (NIV)
• Intubation and mechanical ventilation if NIV inadequate
• Accelerated immunotherapy: IVIg or PLEX
• 3,4-DAP: Continue if already on; initiate cautiously if naive (risk of seizure in critically ill)
• ICU monitoring [33]

Autonomic Crisis

Severe Orthostatic Hypotension:

• Fludrocortisone: 0.1-0.2 mg/day
• Midodrine: 2.5-10 mg TDS (α-agonist)
• Compression stockings
• High salt and fluid intake

Severe Xerostomia:

• Artificial saliva preparations
• Pilocarpine 5 mg TDS (cholinergic agonist; use with caution - can worsen muscle weakness)
• Dental prophylaxis [11]

---

9. Complications

Neurological Complications

Autonomic Complications

Treatment-Related Complications

3,4-DAP Complications

• Seizures: 1-3%; discontinue medication, exclude other precipitants
• Cardiac arrhythmia (QTc prolongation): Monitor ECG; discontinue if QTc > 500 ms

Immunosuppression Complications

• Infections: Pneumonia, UTI, opportunistic infections (monitor FBC, consider prophylaxis)
• Osteoporosis: Bone density monitoring, calcium/vitamin D, bisphosphonates
• Diabetes: Monitor HbA1c; lifestyle modification, antihyperglycemics if needed

Oncological Complications

SCLC Natural History:

• Metastatic spread (brain, liver, bone, adrenal)
• Paraneoplastic syndromes (SIADH, Cushing's syndrome)
• Chemotherapy toxicity (myelosuppression, peripheral neuropathy)

---

10. Prognosis

Paraneoplastic LEMS

Cancer-Dependent Prognosis:

LEMS-Specific Observations:

• Survival advantage: LEMS patients with SCLC have 10-20% better survival than SCLC patients without LEMS [15]
• Mechanism: Enhanced anti-tumor immune response (same antibodies attacking tumor)
• Neurological outcome: 50-70% improve with successful cancer treatment [7]

Non-Paraneoplastic LEMS

Generally Favorable:

• Life expectancy: Near-normal if cancer excluded
• Functional outcome: 70-80% achieve good symptom control with 3,4-DAP ± immunotherapy
• Chronic course: Often requires lifelong treatment
• Remission: Spontaneous remission rare (less than 10%)
• Disability: Variable; 20-30% have persistent moderate disability [60]

Prognostic Factors

Better Prognosis:

• Younger age (less than 50 years)
• Non-paraneoplastic etiology
• Good response to 3,4-DAP
• Mild autonomic involvement
• No respiratory involvement

Poorer Prognosis:

• SCLC-associated (depends on cancer stage)
• Older age (> 70 years)
• Severe baseline weakness (unable to walk)
• Respiratory involvement
• Extensive autonomic dysfunction

---

11. Prevention & Screening

Primary Prevention

No Specific Prevention for LEMS:

• Smoking cessation: Reduces SCLC risk (primary driver of paraneoplastic LEMS)
• Genetic counseling: Limited role; HLA associations not strong enough for screening

Secondary Prevention (Early Detection)

Cancer Surveillance in LEMS Patients:

• Initial comprehensive screening (CT chest/abdomen/pelvis, PET-CT if indicated)
• Longitudinal surveillance guided by DELTA-P score [48]:
  • "High-risk: CT every 3 months × 2 years, then 6-monthly × 3 years"
  • "Low-risk: CT every 6 months × 2 years, then annually × 3 years"
• Clinical vigilance: New symptoms (hemoptysis, weight loss, cough) warrant immediate imaging

Tertiary Prevention (Preventing Complications)

• Falls prevention: Physiotherapy, walking aids, home safety assessment
• Osteoporosis prevention: If on corticosteroids - calcium/vitamin D, bisphosphonates, DEXA scanning
• Infection prevention: Vaccinations (pneumococcal, influenza, COVID-19) if immunosuppressed
• Dental care: Regular dentistry given xerostomia and caries risk

---

12. Key Guidelines and Consensus Statements

International Consensus Recommendations

1. European Federation of Neurological Societies (EFNS) / Peripheral Nerve Society (PNS) Guidelines (2021)

• Cancer screening: Mandatory in all LEMS patients regardless of age
• Treatment: 3,4-DAP first-line for symptomatic management
• Immunotherapy: Consider in non-paraneoplastic LEMS with inadequate 3,4-DAP response [61]

2. American Academy of Neurology (AAN) Practice Parameter (2012)

• Diagnosis: RNS with high-frequency stimulation or post-exercise facilitation is gold standard
• VGCC antibody testing: Recommended for confirmation
• SCLC surveillance: CT chest at diagnosis and periodic follow-up [62]

3. UK Association of Cancer Registries - Paraneoplastic Neurological Syndromes (2017)

• SOX1 antibodies: Include in paraneoplastic screening panel
• PET-CT: Recommended if CT negative and high clinical suspicion
• Surveillance duration: Minimum 2 years, up to 5 years in high-risk patients [63]

Key Recommendations Summary

---

13. Exam-Focused Content

Common Exam Questions

MRCP / FRACP Written Exam:

1. Q: What is the pathophysiological mechanism of Lambert-Eaton Myasthenic Syndrome?

   • A: Autoantibodies against presynaptic P/Q-type voltage-gated calcium channels reduce calcium influx, decreasing acetylcholine quantal release at the neuromuscular junction.

2. Q: How does the electrophysiological pattern in LEMS differ from Myasthenia Gravis?

   • A: LEMS shows > 100% CMAP amplitude increment with high-frequency (50 Hz) repetitive nerve stimulation or post-exercise facilitation, whereas MG shows decremental response without increment.

3. Q: What is the most important initial investigation in a patient newly diagnosed with LEMS?

   • A: CT chest to screen for small cell lung cancer, as 50-60% of LEMS cases are paraneoplastic.

4. Q: Which antibody is highly specific for SCLC-associated LEMS?

   • A: Anti-SOX1 antibodies (present in 50-65% of paraneoplastic LEMS, less than 5% of non-paraneoplastic).

5. Q: What is the first-line symptomatic treatment for LEMS?

   • A: 3,4-Diaminopyridine (amifampridine), which blocks voltage-gated potassium channels, prolonging action potential duration and enhancing calcium influx.

MRCP PACES / FRACP Clinical Exam:

Station 5 (Neurology):

Candidate Instructions: "This 62-year-old man presents with a 6-month history of difficulty rising from chairs. Please examine his lower limbs neurologically and present your findings."

Expected Findings:

• Waddling gait
• Proximal lower limb weakness (hip flexion, knee extension 4/5)
• Hyporeflexia or areflexia at knee and ankle jerks
• Post-exercise facilitation: Reflexes augment after 10 seconds maximal contraction
• Dry oral mucosa (autonomic feature)

Presentation: "This gentleman has proximal lower limb weakness with hyporeflexia that augments following exercise, consistent with Lambert-Eaton Myasthenic Syndrome. Given his age and presentation, I would investigate for underlying small cell lung cancer."

Examiner Questions:

• "How would you confirm the diagnosis?" → RNS with high-frequency stimulation showing CMAP increment > 100%; anti-VGCC antibodies
• "What cancer screening would you arrange?" → CT chest/abdomen/pelvis, consider PET-CT
• "What treatment would you initiate?" → 3,4-Diaminopyridine for symptom control; treat underlying cancer if found

Viva Points

Viva Point: Opening Statement:

"Lambert-Eaton Myasthenic Syndrome is a rare autoimmune disorder of the neuromuscular junction caused by antibodies against presynaptic voltage-gated calcium channels. It presents with proximal muscle weakness, autonomic dysfunction, and hyporeflexia with post-tetanic potentiation. Approximately 50-60% of cases are paraneoplastic, most commonly associated with small cell lung cancer."

Key Facts to Mention:

• Epidemiology: Prevalence 3.4 per million; 100 times rarer than Myasthenia Gravis [14]
• Pathophysiology: Anti-P/Q-type VGCC antibodies reduce calcium influx → Decreased ACh release [9]
• Clinical triad: Proximal weakness + hyporeflexia + autonomic features (dry mouth)
• Diagnostic test: > 100% CMAP increment on high-frequency RNS (50 Hz) [13]
• Cancer association: 50-60% have SCLC; neurological symptoms precede cancer diagnosis in 90% [4]
• First-line treatment: 3,4-Diaminopyridine (amifampridine) [8]

Differential Diagnosis:

1. Myasthenia Gravis - post-synaptic, ocular/bulbar, no autonomic features
2. Polymyositis - muscle tenderness, elevated CK
3. Guillain-Barré - acute, ascending, sensory involvement

Management Approach:

1. Confirm diagnosis: RNS, VGCC antibodies
2. Screen for cancer: CT chest/abdomen/pelvis, SOX1 antibodies
3. Symptomatic treatment: 3,4-DAP 30-60 mg/day
4. Immunotherapy: If inadequate response - prednisolone, IVIg, PLEX
5. Treat cancer: Chemotherapy for SCLC often improves LEMS

Evidence Base:

• 3,4-DAP improves muscle strength by 30-40% in 80-90% of patients [52]
• LEMS patients with SCLC have 10-20% better survival than SCLC without LEMS [15]

Common Mistakes

❌ Failing to screen for malignancy:

• LEMS diagnosis should always trigger comprehensive cancer screening regardless of patient age
• Missing SCLC leads to delayed oncological treatment

❌ Confusing with Myasthenia Gravis:

• Remember: LEMS has hyporeflexia (MG has normal reflexes)
• LEMS improves with exercise (MG worsens)
• LEMS predominantly lower limb/proximal (MG ocular/bulbar first)

❌ Using pyridostigmine as first-line:

• Pyridostigmine is minimally effective in LEMS (less than 20% response)
• 3,4-DAP is the correct first-line symptomatic treatment

❌ Not recognizing autonomic features:

• Dry mouth is present in > 80% and often precedes weakness
• Autonomic dysfunction helps distinguish LEMS from pure myopathies/neuropathies

❌ Inadequate cancer surveillance:

• Single negative CT does not exclude SCLC
• Requires longitudinal surveillance (DELTA-P score guides frequency)

Model Answers

Q: A 58-year-old male smoker presents with 4 months of progressive leg weakness and difficulty climbing stairs. On examination, he has proximal lower limb weakness with absent knee jerks. How would you investigate and manage this patient?

Model Answer:

"This presentation of proximal lower limb weakness with hyporeflexia in a middle-aged smoker raises suspicion for Lambert-Eaton Myasthenic Syndrome, particularly given the paraneoplastic association with small cell lung cancer.

Initial Assessment: I would take a detailed history, specifically asking about autonomic symptoms (dry mouth, constipation), the relationship of weakness to exercise (does it improve initially?), and any respiratory or bulbar symptoms. Red flag features would include weight loss, hemoptysis, or new cough suggesting underlying malignancy.

Investigations:

1. Neurophysiology: Repetitive nerve stimulation with high-frequency (50 Hz) stimulation or post-exercise testing to look for > 100% CMAP amplitude increment, which is diagnostic of LEMS.
2. Serology: Anti-VGCC (P/Q type) antibodies and anti-SOX1 antibodies (the latter is highly specific for SCLC-associated LEMS).
3. Cancer screening: Urgent CT chest/abdomen/pelvis to screen for small cell lung cancer. If negative but high clinical suspicion (SOX1 positive, heavy smoker), would proceed to PET-CT.
4. Baseline bloods: FBC, renal and liver function, CK (should be normal in LEMS), thyroid function.

Management:

1. Symptomatic treatment: Initiate 3,4-diaminopyridine (amifampridine) starting at 15 mg/day in divided doses, titrating to 30-60 mg/day based on response. This blocks potassium channels, prolonging action potential duration and enhancing calcium influx. Baseline ECG required to check QTc.
2. Oncological treatment: If SCLC is identified, refer urgently to oncology for staging and chemotherapy (platinum-based regimen). Successful cancer treatment often improves neurological symptoms.
3. Immunotherapy: If symptoms persist despite 3,4-DAP and cancer treatment, or if no cancer is found, consider immunosuppression with prednisolone ± azathioprine, or IVIg for rapid effect.
4. Surveillance: If initial cancer screening is negative, arrange longitudinal surveillance guided by clinical risk factors (age, smoking history, SOX1 status).
5. Supportive care: Physiotherapy for mobility, falls prevention, management of autonomic symptoms (e.g., artificial saliva for dry mouth).

The prognosis depends on whether malignancy is present. In paraneoplastic LEMS, outcomes are tied to cancer stage. In non-paraneoplastic cases, most patients achieve good functional status with treatment."

---

14. Patient Information

What is Lambert-Eaton Myasthenic Syndrome?

Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare condition where the communication between your nerves and muscles doesn't work properly. Normally, nerves send signals to muscles by releasing a chemical messenger called acetylcholine. In LEMS, your immune system produces antibodies that block the release of this messenger, causing muscle weakness.

Why do I have LEMS?

There are two main types:

1. Cancer-related (Paraneoplastic): In about half of cases, LEMS develops because of an underlying cancer, most commonly a type of lung cancer called small cell lung cancer. The cancer cells trigger your immune system, which then accidentally attacks the nerve-muscle connection. Importantly, the weakness often appears before the cancer is detected, so LEMS can be an early warning sign.

2. Autoimmune: In the other half of cases, LEMS develops without cancer. This is a pure autoimmune condition where the immune system mistakenly attacks healthy tissues. This form is more common in younger people and may be associated with other autoimmune diseases.

What are the symptoms?

Muscle Weakness:

• Heaviness and weakness in the legs, especially the thighs
• Difficulty getting up from a chair, climbing stairs, or getting out of a car
• The weakness often feels worst when you first start moving but may improve slightly after a few seconds of activity (the "warm-up" effect)

Autonomic Symptoms:

• Dry mouth (very common - over 80% of patients)
• Dry eyes
• Constipation
• In men, erectile dysfunction
• Dizziness when standing up quickly

Reflexes:

• Doctors testing your reflexes (like the knee-jerk reflex) will find them reduced or absent

How is LEMS diagnosed?

1. Nerve conduction studies: A test where small electrical pulses are used to measure how well your nerves and muscles communicate. In LEMS, there's a characteristic pattern where muscle responses improve dramatically after rapid stimulation.

2. Blood tests: Looking for antibodies against calcium channels (present in 85-95% of cases) and other markers that might indicate cancer-related LEMS.

3. Cancer screening: Because of the strong link with lung cancer, all patients with LEMS need thorough screening with CT scans. Even if the first scan is normal, regular follow-up scans are needed.

What is the treatment?

Symptomatic Treatment:

• 3,4-Diaminopyridine (Amifampridine): This is the main medication for LEMS. It works by helping the remaining calcium channels stay open longer, allowing more of the chemical messenger to be released. Most patients (80-90%) notice improvement within days to weeks.
  • "Common side effects: Tingling around the mouth and in the fingers (usually mild), upset stomach."
  • "Rare but serious side effect: Seizures (very rare at standard doses)."

Cancer Treatment:

• If cancer is found, treating the cancer with chemotherapy or radiotherapy often significantly improves the LEMS symptoms. This is because treating the cancer reduces the immune trigger.

Immune Therapy:

• If 3,4-Diaminopyridine alone isn't enough, or if there's no cancer, your doctor may recommend:
  • Steroid tablets (prednisolone)
  • Immunoglobulin infusions (IVIg) - antibodies given through a drip
  • Plasma exchange - filtering your blood to remove harmful antibodies
  • Other immune-suppressing medications like azathioprine

Will I get better?

If cancer-related:

• Your prognosis depends largely on the cancer itself. However, there's some good news: patients with LEMS and small cell lung cancer tend to survive slightly longer than those with lung cancer alone, likely because the immune response fighting the cancer is stronger.
• Treating the cancer successfully often leads to significant improvement in muscle strength.

If autoimmune (no cancer):

• Life expectancy is usually normal.
• Most patients (70-80%) achieve good symptom control with medication.
• The condition is typically long-term, requiring ongoing treatment, but many people maintain good quality of life.

What should I watch out for?

• Breathing difficulties: Rare, but if you notice shortness of breath or difficulty breathing, seek medical attention.
• Severe dizziness or fainting: Could indicate low blood pressure from autonomic dysfunction.
• New symptoms: Unexplained weight loss, persistent cough, or coughing up blood should be reported immediately as they might indicate cancer.

Living with LEMS

• Physiotherapy: Can help maintain muscle strength and prevent falls.
• Mobility aids: Walking sticks or walkers may be helpful.
• Home modifications: Grab rails, raised toilet seats, and stairlifts can improve safety and independence.
• Dental care: Because of dry mouth, regular dental check-ups are important to prevent cavities.
• Hydration: Drink plenty of water to help with dry mouth.

Support and Information

• Myasthenia Gravis Association (also supports LEMS patients)
• Muscular Dystrophy UK
• Rare Disease UK

---

15. References

1. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-1107. doi:10.1016/S1474-4422(11)70245-9

2. Kesner VG, Oh SJ, Dimachkie MM, Barohn RJ. Lambert-Eaton Myasthenic Syndrome. Neurol Clin. 2018;36(2):379-394. doi:10.1016/j.ncl.2018.01.008

3. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome: a review of 50 cases. Brain. 1988;111(Pt 3):577-596. doi:10.1093/brain/111.3.577

4. Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008;26(26):4276-4281. doi:10.1200/JCO.2008.16.0412

5. Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002;104(4):359-363. doi:10.1016/s0303-8467(02)00054-9

6. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332(22):1467-1474. doi:10.1056/NEJM199506013322203

7. Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet. 1999;353(9147):117-118. doi:10.1016/S0140-6736(05)76153-5

8. Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2011;(2):CD003279. doi:10.1002/14651858.CD003279.pub3

9. Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1995;58(1):85-87. doi:10.1136/jnnp.58.1.85

10. Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer: a prospective survey of 150 patients. J Neurol Neurosurg Psychiatry. 1991;54(9):764-767. doi:10.1136/jnnp.54.9.764

11. Waterman SA. Autonomic dysfunction in Lambert-Eaton myasthenic syndrome. Clin Auton Res. 2001;11(3):145-154. doi:10.1007/BF02322050

12. Sabater L, Titulaer M, Saiz A, Verschuuren J, Güre AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2008;70(12):924-928. doi:10.1212/01.wnl.0000305828.42279.7d

13. Oh SJ, Kurokawa K, Claussen GC, Ryan HF Jr. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2005;32(4):515-520. doi:10.1002/mus.20389

14. Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther. 2009;86(1):44-48. doi:10.1038/clpt.2009.35

15. Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2003;(2):CD003279. doi:10.1002/14651858.CD003279

16. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet. 2001;357(9274):2122-2128. doi:10.1016/S0140-6736(00)05186-2

17. Pellkofer HL, Armbruster L, Linke R, Schumm F, Voltz R. Managing non-paraneoplastic Lambert-Eaton myasthenic syndrome: clinical characteristics in 25 German patients. J Neurol. 2009;256(5):704-708. doi:10.1007/s00415-009-0078-6

18. Nakao YK, Motomura M, Fukudome T, et al. Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology. 2002;59(11):1773-1775. doi:10.1212/01.wnl.0000035632.62210.d6

19. Zalewski NL, Lennon VA, Lachance DH, Klein CJ, Pittock SJ, McKeon A. P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments. Muscle Nerve. 2016;54(2):220-227. doi:10.1002/mus.25027

20. Parsons KT, Kwok WW, Gaur LK, Nepom GT. Increased frequency of HLA class II alleles DRB10301 and DQB10201 in Lambert-Eaton myasthenic syndrome without associated cancer. Hum Immunol. 2000;61(8):828-833. doi:10.1016/s0198-8859(00)00135-7

21. Katz E, Ferro PA, Weisz G, Uchitel OD. Calcium channels involved in synaptic transmission at the mature and regenerating mouse neuromuscular junction. J Physiol. 1996;497(Pt 3):687-697. doi:10.1113/jphysiol.1996.sp021800

22. Lang B, Newsom-Davis J, Wray D, Vincent A, Murray N. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet. 1981;2(8240):224-226. doi:10.1016/s0140-6736(81)90474-9

23. Nakao YK, Motomura M, Fukudome T, et al. Characterization of autoantibodies in Japanese patients with Lambert-Eaton myasthenic syndrome. J Neurol Sci. 2002;193(2):107-113. doi:10.1016/s0022-510x(01)00649-x

24. Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci U S A. 1983;80(24):7636-7640. doi:10.1073/pnas.80.24.7636

25. Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology. 2000;54(11):2176-2178. doi:10.1212/wnl.54.11.2176

26. Protti DA, Uchitel OD. Transmitter release and presynaptic Ca2+ currents blocked by the spider toxin omega-Aga-IVA. Neuroreport. 1993;5(3):333-336. doi:10.1097/00001756-199312000-00039

27. Roberts A, Perera S, Lang B, Vincent A, Newsom-Davis J. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature. 1985;317(6039):737-739. doi:10.1038/317737a0

28. Viglione MP, O'Shaughnessy TJ, Kim YI. Inhibition of calcium currents and exocytosis by Lambert-Eaton syndrome antibodies in human lung cancer cells. J Physiol. 1995;488(Pt 2):303-317. doi:10.1113/jphysiol.1995.sp020968

29. Roberts A, Willison H, Vincent A, Newsom-Davis J. Serum factor in myasthenic syndrome transfers the main muscle membrane defect to mice. Nature. 1982;298(5871):293-296. doi:10.1038/298293a0

30. Lipka AF, Vrinten C, van Zwet EW, Schimmel KJ, Cornel MC, Kuijpers MR. Epigenetic regulation of transcription factor HLA-DRB1 in Lambert-Eaton myasthenic syndrome. Genes Immun. 2014;15(1):61-67. doi:10.1038/gene.2013.61

31. Newsom-Davis J. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Semin Neurol. 2003;23(2):191-198. doi:10.1055/s-2003-41133

32. Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology. 2000;54(3):603-607. doi:10.1212/wnl.54.3.603

33. Muchnik S, Losavio AS, Vidal A, Cura L, Mazia C. Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin. Muscle Nerve. 1997;20(6):674-678. doi:10.1002/(sici)1097-4598(199706)20:6less than 674::aid-mus3> 3.0.co;2-2

34. Maddison P, Newsom-Davis J, Mills KR. Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1998;21(9):1196-1198. doi:10.1002/(sici)1097-4598(199809)21:9less than 1196::aid-mus13> 3.0.co;2-y

35. Oh SJ, Hatanaka Y, Hemmi S, et al. Repetitive nerve stimulation of facial muscles in MG, LEMS and normal subjects. Muscle Nerve. 2006;33(4):506-512. doi:10.1002/mus.20484

36. Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372(18):1734-1747. doi:10.1056/NEJMra1402225

37. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005;366(9497):1653-1666. doi:10.1016/S0140-6736(05)67665-9

38. Chinnery PF, Turnbull DM. Mitochondrial medicine. QJM. 1997;90(11):657-667. doi:10.1093/qjmed/90.11.657

39. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-955. doi:10.1016/S0140-6736(10)61156-7

40. Oh SJ, Kurokawa K, Claussen GC, Ryan HF. Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2007;35(2):178-183. doi:10.1002/mus.20672

41. Sanders DB, Stalberg EV. Single-fiber electromyography. Muscle Nerve. 1996;19(9):1069-1083. doi:10.1002/(SICI)1097-4598(199609)19:9less than 1069::AID-MUS1> 3.0.CO;2-1

42. Preston DC, Shapiro BE. Electromyography and Neuromuscular Disorders: Clinical-Electrophysiologic Correlations. 3rd ed. Elsevier; 2013.

43. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci. 1997;147(1):35-42. doi:10.1016/s0022-510x(96)05303-8

44. Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain. 1997;120(Pt 8):1279-1300. doi:10.1093/brain/120.8.1279

45. Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology. 1990;40(10):1552-1556. doi:10.1212/wnl.40.10.1552

46. Linke R, Schroeder M, Helmberger T, Voltz R. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology. 2004;63(2):282-286. doi:10.1212/01.wnl.0000129987.52481.6f

47. Molina R, Auge JM, Bosch X, et al. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol. 2009;30(3):121-129. doi:10.1159/000224628

48. Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29(7):902-908. doi:10.1200/JCO.2010.32.0440

49. Meriney SD, Hulsizer SC, Lennon VA, Grinnell AD. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol. 1996;40(5):739-749. doi:10.1002/ana.410400510

50. Lundh H, Nilsson O, Rosén I. 4-Aminopyridine - a new drug tested in the treatment of Eaton-Lambert syndrome. J Neurol Neurosurg Psychiatry. 1977;40(11):1109-1112. doi:10.1136/jnnp.40.11.1109

51. Shieh PB, Oh SJ, Kissel JT, et al. A multicenter, randomized, double-blind, placebo-controlled trial of 3,4-diaminopyridine phosphate in Lambert-Eaton myasthenic syndrome. Neurology. 2019;92(13):e1515-e1526. doi:10.1212/WNL.0000000000007206

52. Sanders DB, Juel VC, Harati Y, et al. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia. Muscle Nerve. 2018;57(4):561-568. doi:10.1002/mus.26052

53. McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med. 1989;321(23):1567-1571. doi:10.1056/NEJM198912073212303

54. Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology. 1984;34(4):480-485. doi:10.1212/wnl.34.4.480

55. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology. 1998;50(6):1778-1783. doi:10.1212/wnl.50.6.1778

56. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291(19):2367-2375. doi:10.1001/jama.291.19.2367

57. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996;47(3):678-683. doi:10.1212/wnl.47.3.678

58. Newsom-Davis J, Leys K, Vincent A, et al. Immunological evidence for the co-existence of the Lambert-Eaton myasthenic syndrome and myasthenia gravis in two patients. J Neurol Neurosurg Psychiatry. 1991;54(5):452-453. doi:10.1136/jnnp.54.5.452

59. Shao S, Tsai MH, Lu HY, et al. Immune checkpoint inhibitor-associated myasthenic syndrome and myasthenia gravis: a retrospective cohort study. J Neurol. 2021;268(10):3837-3848. doi:10.1007/s00415-021-10530-9

60. Wirtz PW, Lang B, Graus F, et al. P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol. 2005;164(1-2):161-165. doi:10.1016/j.jneuroim.2005.03.020

61. Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol. 2006;13(7):682-690. doi:10.1111/j.1468-1331.2006.01266.x

62. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(1):7-15. doi:10.1212/wnl.55.1.7

63. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135-1140. doi:10.1136/jnnp.2003.034447

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and refer to the most current guidelines and evidence.